Facebook
Twitter
LinkedIn
Forward
Diagnostic Decisions: Practical Strategies to Accurately Identify Ocular Surface Diseases (CME/CE Monograph)
Activity Description and Purpose
Corneal nerves have an essential role in maintaining ocular surface health and homeostasis. Manifestations of neurosensory abnormalities affecting corneal innervation include dry eye disease, neurotrophic keratopathy, and neuropathic corneal pain. These conditions can exist as a standalone entity, but they can also be concurrent and have overlapping features, making diagnosis challenging. Early diagnosis of dry eye disease, neurotrophic keratopathy, and neuropathic corneal pain is important to allow intervention that can help to restore function and improve quality of life. This educational activity reviews common diagnostic modalities that can be used by clinicians to identify these conditions.
Target Audience
This educational activity is intended for ophthalmologists and optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Review diagnostic modalities used for proper assessment of ocular surface disease
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
Faculty
 | Kendall E. Donaldson, MD, MS (Co-Chair) Professor of Clinical Ophthalmology Medical Director Bascom Palmer Eye Institute in Plantation Plantation, Florida |
 | Douglas K. Devries, OD (Co-Chair) Associate Clinical Professor Pacific University College of Optometry Co-Founder Advanced Vision and Laser Center Reno, Nevada |
 | Nathan Lighthizer, OD Associate Dean and Associate Professor Chief, Specialty Care Clinics Northeastern State University College of Optometry Tahlequah, Oklahoma |
 | Christopher E. Starr, MD, FACS
|
Disclosure Policy
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Faculty
Douglas K. Devries, OD, is a consultant for Alcon, Allergan, Avellino, Azura Ophthalmics Ltd, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, Thea Pharmaceuticals Limited, and Visus Therapeutics; and is on the speakers bureau for Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, OCuSOFT Inc, Oyster Point Pharma, Inc, ScienceBased Health, Sight Sciences, and Sun Pharmaceutical Industries, Inc.
Kendall E. Donaldson, MD, MS, is a consultant for AcuFocus, Inc, Alcon, Allergan, Bausch & Lomb Incorporated, Dompé US, Inc, Eyevance, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Lumenis, Omeros Corporation, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Zeiss.
Nathan Lighthizer, OD, is a consultant for Diopsys, Inc, and OCuSOFT; is an advisory board member of Bruder Healthcare, EyePromise, Horizon Therapeutics plc, Novartis Pharmaceuticals Corporation, Orasis Pharmaceuticals, and Sight Sciences; and is on the speakers bureau for Dompé US, Inc, Ellex, and Sun Pharmaceutical Industries, Inc.
Christopher E. Starr, MD, is a consultant for Aerie Pharmaceuticals, Inc, Aldeyra Therapeutics, Allergan, Bruder Healthcare, Dompé US, Inc, EyeBio, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Quidel Corporation, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, TearLab Corporation, and Verséa Health, Inc; and has individual stocks or stock options in Èssiri Labs.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Cheryl Guttman Krader has individual stocks in Johnson & Johnson Vision Care, Inc.
Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 1.0 CE credit for optometrists.
COPE Course ID: 85210-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator: 
Disclosure of Commercial Support
MedEdicus has received commercial support from Dompé US, Inc, for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Dompé US, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 266.2
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 COPE
- 1.00 Participation